Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

ly there is no marketed treatment for DGF; when DGF is diagnosed the patient is supported with dialysis and other supportive care.

The investigational drug candidate QPI-1002 is a siRNA designed to temporarily inhibit the expression of the pro-apoptotic gene, p53. This siRNA is based on Quark's proprietary, patented therapeutic concept of temporarily inhibiting the expression of p53 to protect normal cells from acute injury. QPI-1002 is a chemically modified siRNA discovered by Quark with structure covered under licenses from Silence Therapeutics and from Alnylam Pharmaceuticals. QPI-1002 was the first systemically administered siRNA in a human clinical study.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. QPI-1007, which is a siRNA that utilizes a novel siRNA structure developed by Quark and is being evaluated in advanced IND-e
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , COLLEGE PARK, Md., Nov. 25 /PRNewswire-US... developing a shaving cream-like foam that stops s... Most Promising Security Idea category of the Glob...unce today. ,, Selected from more than 100 entr... their invention at the GSC Security Summit confer...
(Date:11/25/2009)... , HARBIN, China, Nov. 25 /PRNewswire...China Sky One Medical" or "the Company") (Nasdaq: ... company developing and producing,over-the-counter...today,announced that the Company recently passed t...harmaceutical and Biological Products ("ICPBP") ex...
(Date:11/25/2009)... , UNION CITY, Calif., Nov. 25 /PRNewswire-Firs... products company manufacturing point-of-care bloo...erson, chairman and chief executive officer, will ...re Conference on Wednesday, December 2, 2009 at 2:... York Palace Hotel in New York City. ,, About ...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 1Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 2Despite Generic Erosion of Key Brands the Hospital Acquired Gram Negative Infections Drug Market Will Increase by 241 Billion from 2008 to 2018 49015 1Despite Generic Erosion of Key Brands the Hospital Acquired Gram Negative Infections Drug Market Will Increase by 241 Billion from 2008 to 2018 49015 2Despite Generic Erosion of Key Brands the Hospital Acquired Gram Negative Infections Drug Market Will Increase by 241 Billion from 2008 to 2018 49015 3AirClic Mobile Business Solutions Clic for Bio Reference Laboratories Inc 49012 1AirClic Mobile Business Solutions Clic for Bio Reference Laboratories Inc 49012 2
...cility Infection Prevention and Control Profession...ombat MRSA Including Additional,Staff, More Enviro...ns, DENVER, June 17 More than three out of four,...ls (ICPs) polled,indicated they have implemented a...methicillin-resistant Staphylococcus aureus (MRSA)...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) to...ual,European Congress of Rheumatology meeting in P... TRU-015, Trubion,s lead candidate for the,treatme...uce persistent,responses on the American College o...acodynamic (PD) effects. In addition, preclinical ...
Other Medicine Technology:Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 2Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 3Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 2Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 3Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 4Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 5
(Date:11/29/2009)... Using mannequins to teach doctors-in-training how...e way to improve their skills without compromising... from Henry Ford Hospital. , The study shows tha...aluable tool to improve medical residents, knowled...f the more common ultrasound-guided procedures, in...
(Date:11/29/2009)...unaware the sleep disorder boosts urine production...thDay News) -- People who wake up during the night...ical problem. Sleep apnea, a breathing-related sle...suggests that nighttime urination, or nocturia, is...ctive sleep apnea, a disorder in which soft tissue...
(Date:11/28/2009)...ers were more likely to consider change after 30-m... , FRIDAY, Nov. 27 (HealthDay News) -- A pro...r why they should stop their dangerous behavior ma...searchers have found. , The new study included ...mpaired convictions, who were randomly assigned to...
(Date:11/27/2009)... Biotech firm Replikins Ltd. today iss...rus genomic data. It shows that the lethality of ....5) during the virus,s current outbreak in the spr...ek of 2.0 (s.d. 0.1). The H1N1 infectivity count, ... Boston (PRWEB) November 27, 2009 -- Biotech f...
(Date:11/27/2009)...BBUTZ SHAMIR, Israel, Nov. 27 /PRNewswire-FirstCal...) ( "Shamir" ), a leading provider of innovative p...et, announced today that its board of directors ha... amount of US$ 10 million (approximately NIS 37.62...tive rate of exchange), or approximately US$ 0.609...
Breaking Medicine News(10 mins):Health News:Simulated training for ultrasound-guided procedures improves safety without risk to patients 2Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3
...ves of Internal Medicine ,a plate and cereal bowl ...lp obese patients with diabetes lose weight and d...ns. Between 1960 and 2000, the proportion of ...tes can be attributed directly to obesity. ...
...hat non-Hispanic white youth have the highest rate...ren in the U.S., with type 1 being the predominan..., M.D., Ph.D., of the University of Colorado Healt...etes mellitus (DM) show an increase in incidence w...
...ng to another level turning back plastics into th...l Resource Corporation (GRC) claims the process re...0 different frequencies within the microwave range...ftovers. As the material is zapped at the ...
...ght management program cuts diabetes risk and is m... mass index (BMI) in overweight children. ...d by researchers at Yale School of Medicine was mo...i, research associate in Yale's Department of Pedi...
...tion of real life experiences of the fight against...f events on Monday on the eve of the International... spirit of recovery', as the event was called, inv...f social justice and empowerment and the United Na...
...dy found that smaller amount of teenagers are drin...use it is becoming harder for youngsters to get h...go up from 12% in 2005 to 17% in the latest resear...ess and of those half confess to becoming aggressi...
Other Medicine News:Health News:Weight Control for Obese Diabetics 2Health News:Whites Have Highest Risk of Diabetes in U.S 2Health News:Bright Bodies Weight Program Lowers Diabetes Risk, BMI in Obese Kids 2Health News:Puppet Show, Music Gives Message - 'say No to Drugs' 2Health News:New Study That Small Amount of Teenagers Drinks on a Regular Basis 2
Replacement Bulb: EFP
Replacement Bulb: EFM
Replacement Bulb: DNE Osram Sylvania
Replacement Bulb: DDL
Medicine Products: